Japan Approves Leqembi Pen for At-Home Alzheimer's Treatment

The Leqembi Pen enables a 500 mg dose administered through two weekly injections, each taking roughly 15 seconds to complete. This development follows a strategic partnership between Sweden’s BioArctic AB and Eisai, the latter of which handles global commercialization. By moving administration to the home, the drug maker anticipates a reduction in the need for dedicated infusion capacity and nurse monitoring at medical facilities.

Regulatory approval is rooted in Phase 3 Clarity AD study data, which demonstrated that once-weekly subcutaneous dosing matches the exposure levels of the bi-weekly intravenous version. Safety data indicates that systemic injection-related reactions occur in only 1.4% of cases, a lower frequency than observed with IV infusions. While the shift offers increased convenience, the protocol mandates that patients or their caregivers receive rigorous training and initial physician supervision before transitioning to self-administered care.